



30 January 2015

Company Announcements Office
Australian Securities Exchange

Quarterly Cash Flow Statement

Nanosonics Limited (ASX: NAN) has today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2014.

Sales for the quarter were \$8.332million, an increase of \$3.719 million or 81% compared with sales generated during the corresponding quarter to 31 December 2013 (\$4.613 million).

Sales for the six months to 31 December 2014 were \$14.339 million, an increase of \$4.659 million or 48% compared with sales generated during the corresponding half year to 31 December 2013 (\$9.680 million).

The cash balance at the end of the quarter was \$23.529 million compared to \$23.557 million at the end of the September 2014 quarter. Additional cash receipts of \$4.84 million were received in January relating to sales in the second quarter.

“The company has a number of significant activities underway which form part of its 2015 strategic plan that includes an investment to relocate to new premises, comprehensive clinical trial programs focussed on infection control and an increasing focus on direct and hybrid sales models globally”, said Michel Kavanagh, Nanosonics Chief Executive Officer and President.

A detailed review of the progress of the business will be provided in conjunction with the release of the Company’s half year results which are expected to be released in the week commencing 16 February 2015.

Michael Kavanagh
CEO / President

For more information please contact:

Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600
Kyahn Williamson, Media Relations, Buchan Consulting on (03) 9866 4722

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company’s first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.

For more information about Nanosonics please visit www.nanosonics.com.au

Appendix 4C

QUARTERLY REPORT

Name of entity

NANOSONICS LIMITED

ABN

11 095 076 896

Quarter ended ("current quarter")

31 December 2014

Consolidated statement of cash flows

Cash flows related to operating activities

	Current quarter \$A'000	Year to date (6 months) \$A'000
1.1 Receipts from customers	6,891	15,790
1.2 Payments for:		
(a) staffing costs	(3,555)	(7,403)
(b) intellectual property	(82)	(175)
(c) quality and regulatory management	(114)	(173)
(d) business development	(286)	(502)
(e) premises, plant and equipment	(250)	(504)
(f) external consultants and advisors	(240)	(604)
(g) other operating costs, including working capital	(2,700)	(4,705)
1.3 Dividends received		
1.4 Interest and other items of a similar nature received	248	301
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes refund received (paid)	19	15
1.7 Other (R&D Tax Incentive/EMDG)	60	60
Net operating cash flows	(9)	2,100

Quarterly Report (4C Statement) for Quarter ended 31 December 2014

	Current quarter \$A'000	Year to date (6 months) \$A'000
1.8 Net operating cash flows (carried forward)	(9)	2,100
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(200)	(412)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
Net investing cash flows	(200)	(412)
1.14 Total operating and investing cash flows	(209)	1,688
Cash flows related to financing activities		
1.15 Proceeds from issue of shares and exercise of options	27	331
1.16 Net proceeds from issue of convertible note	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	(1)	(3)
1.19 Dividends paid	-	-
1.20 Capital raising costs recovered	-	-
Net financing cash flows	26	328
Net increase (decrease) in cash held	(183)	2,016
1.21 Cash at beginning of quarter/year to date	23,557	21,233
1.22 Exchange rate adjustments to item 1.21	155	280
1.23 Cash at end of quarter	23,529	23,529

Quarterly Report (4C Statement) for Quarter ended 31 December 2014

Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	130
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
Payments are for rent to, and various services provided by director-related entities. Costs are determined on an arms length basis. Rent is at market rate determined by independent valuers.		

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

None

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	41	21
3.2	Credit standby arrangements	150	7
3.3	Guarantee facilities	410	297

Quarterly Report (4C Statement) for Quarter ended 31 December 2014

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	3,483	2,229
4.2 Deposits at call	2,518	1,080
4.3 Bank overdraft	-	-
4.4 Term deposits	17,528	20,248
4.5 Floating rate notes	-	-
4.6 Fixed rate notes	-	-
Total: cash at end of quarter (item 1.23)	23,529	23,557

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for Incorporation		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- This statement does ~~does not~~* (delete one) give a true and fair view of the matters disclosed.

Sign here:



Date: 30 January 2015

Print name: Michael Kavanagh
CEO/Managing Director